#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Primary hyperoxaluria Diffuse large B-cell lymphoma refractory Autoimmune haemolytic anaemia Congenital absence of bile ducts Fusarium infection Craniocerebral injury Neoplasm malignant Immunodeficiency Demyelination General anaesthesia Adenocarcinoma pancreas Non-Hodgkin's lymphoma refractory Angiosarcoma non-metastatic Malignant fibrous histiocytoma Richter's syndrome More trials…

    Learn about Rare Diseases

    Isodicentric chromosome 15 syndrome – Trials in Disease Hereditary hypophosphataemic rickets Idiopathic inflammatory myopathy – Life with Disease Gaucher’s disease type III – Basic Information Medulloblastoma recurrent Anaplastic thyroid cancer Mucopolysaccharidosis – Trials in Disease Focal segmental glomerulosclerosis – Treatment Synovial sarcoma metastatic Retinitis pigmentosa – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Oxcarbazepine Ethanol, Anhydrous Entinostat Aminohippuric Acid Varnimcabtagene Autoleucel CAL101 Indacaterol Maleate Tiotropium Morf-057 Prs-344 Bicalutamide Sqy51 Follitropin Beta BI-1607 Capivasertib Cloxacillin Sodium COLESEVELAM HYDROCHLORIDE Doxorubicin Hydrochloride Pertuzumab Oxytocin Synthetic More therapies…

    Learn about Your Condition

    Viral infection Small cell lung cancer Breast proliferative changes Hand fracture Pleomorphic liposarcoma Malignant fibrous histiocytoma Breast cancer stage IV Colorectal cancer stage III Leiomyosarcoma metastatic Respiratory tract infection Penile squamous cell carcinoma Immunosuppression Cardiac valve disease Pancreatitis relapsing Indolent systemic mastocytosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Fejer Varmegyei Szent Gyoergy Egyetemi Oktato Korhaz…

Fejer Varmegyei Szent Gyoergy Egyetemi Oktato Korhaz

Sbbalobhory Us 3m Sescuuwisfblnhs 8nqkz Hbqcjxj

Want to learn more about this study or check if you can participate? Contact us.

  • Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Durvalumab
    • Infliximab
    • Mycophenolate Mofetil
    Belgium Bulgaria Czechia France Germany Greece +5

  • Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

    Recruiting

    2 1
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +9

  • Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

    Recruiting

    3 1
    Investigated Drugs:
    • Zasocitinib
    Belgium Bulgaria Croatia Czechia Estonia France +7

  • RO7795068 for Weight Loss in Adults With Obesity or Overweight Without Type 2 Diabetes

    Recruiting

    3 1
    Belgium Czechia France Germany Hungary Italy +3

  • Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Hydroxocobalamin
    • Sotorasib
    • Betamethasone Sodium Phosphate Ph. Eur
    Austria Belgium Bulgaria Czechia Denmark France +11

  • A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ischaemic stroke
    Investigated Drugs:
    • Tenecteplase
    Bulgaria Greece Hungary Norway Romania Spain

  • Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Carboplatin
    • Infliximab
    • Mycophenolate Mofetil
    Austria Belgium France Germany Hungary Italy +3

  • A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +10

  • Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • GSK5764227
    • Topotecan
    Bulgaria Finland France Germany Greece Hungary +7

  • Comparison of SRSD107 and enoxaparin to prevent blood clots in adults undergoing knee replacement surgery

    Recruiting

    2 1 1
    Investigated Diseases:
    • Embolism venous
    Investigated Drugs:
    • SRSD107
    • Enoxaparin Sodium
    Bulgaria Czechia Hungary Latvia Lithuania Poland
1 2 3 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!